195 related articles for article (PubMed ID: 23075044)
1. Small molecules that target protein misfolding.
Gavrin LK; Denny RA; Saiah E
J Med Chem; 2012 Dec; 55(24):10823-43. PubMed ID: 23075044
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in targeting protein misfolding diseases.
Denny RA; Gavrin LK; Saiah E
Bioorg Med Chem Lett; 2013 Apr; 23(7):1935-44. PubMed ID: 23454013
[TBL] [Abstract][Full Text] [Related]
3. Protein Misfolding Diseases and Therapeutic Approaches.
Yadav K; Yadav A; Vashistha P; Pandey VP; Dwivedi UN
Curr Protein Pept Sci; 2019; 20(12):1226-1245. PubMed ID: 31187709
[TBL] [Abstract][Full Text] [Related]
4. Pressure-temperature folding landscape in proteins involved in neurodegenerative diseases and cancer.
Cordeiro Y; Foguel D; Silva JL
Biophys Chem; 2013 Dec; 183():9-18. PubMed ID: 23849959
[TBL] [Abstract][Full Text] [Related]
5. Protein-misfolding diseases and chaperone-based therapeutic approaches.
Chaudhuri TK; Paul S
FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
[TBL] [Abstract][Full Text] [Related]
6. Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form.
Kerman A; Liu HN; Croul S; Bilbao J; Rogaeva E; Zinman L; Robertson J; Chakrabartty A
Acta Neuropathol; 2010 Mar; 119(3):335-44. PubMed ID: 20111867
[TBL] [Abstract][Full Text] [Related]
7. Protein disulphide isomerase protects against protein aggregation and is S-nitrosylated in amyotrophic lateral sclerosis.
Walker AK; Farg MA; Bye CR; McLean CA; Horne MK; Atkin JD
Brain; 2010 Jan; 133(Pt 1):105-16. PubMed ID: 19903735
[TBL] [Abstract][Full Text] [Related]
8. Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis.
Mulligan VK; Chakrabartty A
Proteins; 2013 Aug; 81(8):1285-303. PubMed ID: 23508986
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of misfolding and conformational change in α1-antitrypsin deficiency.
Nyon MP; Gooptu B
Future Med Chem; 2014 Jun; 6(9):1047-65. PubMed ID: 25068987
[TBL] [Abstract][Full Text] [Related]
10. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
Yoshida K; Higuchi K; Ikeda S
Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
[TBL] [Abstract][Full Text] [Related]
11. Protein misfolding in disease and small molecule therapies.
Gomes CM
Curr Top Med Chem; 2012; 12(22):2460-9. PubMed ID: 23339300
[TBL] [Abstract][Full Text] [Related]
12. Neurodegenerative diseases linked to misfolded proteins and their therapeutic approaches: A review.
Khanam H; Ali A; Asif M; Shamsuzzaman
Eur J Med Chem; 2016 Nov; 124():1121-1141. PubMed ID: 27597727
[TBL] [Abstract][Full Text] [Related]
13. Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins.
Naeem A; Fazili NA
Cell Biochem Biophys; 2011 Nov; 61(2):237-50. PubMed ID: 21573992
[TBL] [Abstract][Full Text] [Related]
14. Animal models for prion-like diseases.
Fernández-Borges N; Eraña H; Venegas V; Elezgarai SR; Harrathi C; Castilla J
Virus Res; 2015 Sep; 207():5-24. PubMed ID: 25907990
[TBL] [Abstract][Full Text] [Related]
15. Prediction of "hot spots" of aggregation in disease-linked polypeptides.
Sánchez de Groot N; Pallarés I; Avilés FX; Vendrell J; Ventura S
BMC Struct Biol; 2005 Sep; 5():18. PubMed ID: 16197548
[TBL] [Abstract][Full Text] [Related]
16. Prion, prionoids and infectious amyloid.
Liberski PP
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S80-4. PubMed ID: 24262195
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies for targeting neurodegenerative protein misfolding disorders.
Scannevin RH
Curr Opin Chem Biol; 2018 Jun; 44():66-74. PubMed ID: 29902695
[TBL] [Abstract][Full Text] [Related]
18. Synthetic prions and other human neurodegenerative proteinopathies.
Le NT; Narkiewicz J; Aulić S; Salzano G; Tran HT; Scaini D; Moda F; Giachin G; Legname G
Virus Res; 2015 Sep; 207():25-37. PubMed ID: 25449570
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathways to polyglutamine aggregation.
Robertson AL; Bottomley SP
Adv Exp Med Biol; 2012; 769():115-24. PubMed ID: 23560307
[TBL] [Abstract][Full Text] [Related]
20. From molecule to molecule and cell to cell: prion-like mechanisms in amyotrophic lateral sclerosis.
Grad LI; Fernando SM; Cashman NR
Neurobiol Dis; 2015 May; 77():257-65. PubMed ID: 25701498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
